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Introduction 
In this issue of JBJI, Sven Åke Hedström and Lars 
Lidgren, two founding members of the European 
Bone and Joint Infection Society (EBJIS), report about 
their cooperation between orthopaedic surgeons and 
infection specialists in bone and joint infections in 
1982 [1]. Due to their pioneering work, the value of 
Infectious Diseases (ID) specialists has found is 
essential ground in Bone and Joint Infections (BJIs). 
BJIs are associated with significant morbidity 
and are a growing global burden. Besides classic ID 
such as spinal tuberculosis which have afflicted 
humans for centuries, and still do in the 21st century, 
newer “maladies” such as orthopaedic implant 
associated infections (OIAIs) are set to rise with 
improved life expectancy and the corresponding 
number of prosthetic joint surgeries performed [2]. In 
this editorial, we aim to review the development of 
the expertise in the field of bone and joint infections 
from various perspectives. 
Historical development of BJI units 
Expertise in modern BJI units grew with 
advances made in the disciplines of orthopaedic 
surgery, infectious diseases, clinical microbiology and 
antibiotic pharmacotherapy [3–5], alongside infection 
prevention and control, pathology, plastic surgery, 
vascular surgery, anaesthesiology and radiology. The 
advent of sulfonamides and penicillin in the 1940s 
dramatically improved the treatment of osteomyelitis, 
which till then was predominantly treated surgically 
with drainage and rest (or the “Orr Method” as 
described by Dr. H. Winnett Orr)[3,4] with less 
conventional therapies such as maggot therapy, 
bacteriophages, refrigeration and salt-water pool 
therapy as adjuncts. The first prosthetic knee joint was 
implanted by the German surgeon Themistocles 
Gluck in 1890 for a joint ravaged by tuberculosis, with 
subsequent pioneering work in knee and hip 
arthroplasties by Charney and Insall in the 1960s and 
1970s, while fracture-fixation with wires was 
described as early as 1775 [6]. While these were a boon 
to restore functionality, it became apparent quickly 
that infections associated with these prostheses could 
be devastating, spurring research in preventive 
strategies (such as antisepsis), diagnosis and 
treatment, with much of the early work driven by 
surgeons such as Lister[6], and orthopaedic surgeons 
such as Charney [6].  
Given the multi-disciplinary approach needed to 
prevent, diagnose and treat BJIs, and expertise needed 
to optimise outcomes, units and bed wards dedicated 
to the treatment of BJIs have developed in facilities 
which are referral centers and who typically perform 
a high volume of surgeries related to BJIs. A 
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non-exhaustive list of examples of such units include 
the Bone Infection Unit, at the Nuffield Orthopaedic 
Centre, Oxford, UK, the Wrightington Hospital 
Orthopaedic Centre of Excellence, Lancashire, UK, the 
Basel University Medical Clinic and Interdisciplinary 
Unit for Orthopaedic Infections, Liestal, Switzerland, 
and the Orthopaedic Infectious Diseases Section at the 
Mayo Clinic, Rochester, MN. In the UK for example, it 
has been proposed that ~3-6 networks be formed 
nationally, with each served by a multidisciplinary 
specialist BJI unit comprising of orthopaedists and ID 
physicians specializing in BJI for patients requiring 
complex revisions (e.g. Ilizarov techniques) or who 
have multidrug resistant infections and multiple 
medical comorbidities. Such units are also supported 
by plastic surgeons with experience in complex 
microsurgical reconstruction, vascular surgeons who 
optimise perfusion and healing, microbiology 
laboratory support and outpatient antimicrobial 
therapy services [7]. In addition, many tertiary 
medical centres world-wide have recognised the 
importance of close liaison between orthopaedists and 
infectious disease specialists with formal training or 
an interest in BJIs and other complex musculoskeletal 
infections.  
Frequency and epidemiology of bone and 
joint infection in clinical practice 
While prosthetic joint infections (PJIs) are 
relatively uncommon in proportion to the volume of 
surgeries performed (~1-2% overall)[8], and BJIs as a 
proportion of all hospitalizations (0.2% nationally in 
one French study [9]), consultations for 
musculoskeletal infections, in general, are very 
common in a hospital ID practice. The same French 
study found that BJI accounted for significant 
morbidity and impact clinically and economically – 
with a prevalence of 54 per 100,000 nationally [9]. 
Studies in different countries and time periods have 
attempted to capture the volume of ID consultations 
for musculoskeletal infections in various ways – these 
have accounted from 7% up to 30% of all ID 
consultations [10–12] and a consultation rate of 7.6 per 
100 admissions arising from the orthopaedics 
department in one Israeli study [10]. BJIs are often the 
most common diagnosis for OPAT, as described in a 
Singaporean study (osteomyelitis being the most 
common indication, comprising 15% of the caseload) 
[13] and Dutch study (BJI comprised 38%) [14], with 
another UK study finding that 15% of emergency 
admissions and referrals (excluding PJI) were 
associated with BJIs or soft tissue infection [15].  
Impact and value of infectious diseases 
consultation on BJIs  
The ID physician with expertise in BJIs may 
bring the following benefits to a patient’s 
management (Figure 1): 
• Recommendation of suitable diagnostic testing 
and adjunctive investigations e.g. sonication, 
prolonged incubation, molecular methods, 
biomarkers, relevant imaging, serologic testing 
depending on epidemiological risk factors and 
presentation, and expertise in interpretation of 
these results 
• Expertise in guiding therapy, e.g. selection of 
appropriate antibiotic and duration based on 
available microbiological results and preferred 
antibiotic choices, treatment of complicated BJIs 
including those caused by MDROs or unusual 
organisms, combination therapy with 
rifampicin-containing regimens for 
staphylococcal PJIs and osteomyelitis, peri- 
operative antibiotic prophylaxis, composition of 
antibiotic cement spacers used intraoperatively, 
transitions from IV to oral therapy, outpatient 
antimicrobial therapy, other adjuncts such as 
hyperbaric oxygen therapy. 
• Monitoring and follow-up, e.g. ensuring 
tolerability of treatment, minimising side effects, 
identifying complications and providing 
alternatives where necessary, determining 
duration including long-term antimicrobial 
suppressive therapy 
Improvement in systems processes in the 
prevention, diagnosis and treatment of BJIs in 
conjunction with the orthopaedist, vascular surgeons, 
clinical microbiologists, anaesthesiologists and 
infection preventionists. Examples of initiatives 
include prevention of BJIs via screening and 
decolonization for S. aureus prior to surgery, 
optimizing and in select cases, individualizing 
antibiotic prophylactic regimens for surgery, 
improving diagnostic yield for BJI by standardizing 
optimizing sampling (e.g. adequate number and type 
of intraoperative samples, culture methodology), 
antibiotic stewardship by determining necessity for 
continued antibiotics or transitioning from IV to oral 
antibiotics.  
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Multiple studies have demonstrated a benefit of 
ID consultations for MRSA bacteremia with reported 
reductions in mortality and relapse [16]. Similar 
mortality benefits have been noted for ID consultation 
in multi-drug resistant organism infections in one 
study which included BJIs [16]. Few studies have 
described the impact of infectious disease 
consultation for BJIs specifically; however, one 2015 
study found that osteomyelitis cases managed by a 
orthopaedist alone (without an ID physician) were 4.6 
times more likely to relapse [16]. A more recent 
analysis of administrative claims data of over 70,000 
index stays for a broad range of common ID 
conditions found that early ID intervention was 
associated with shorter hospital stays, lower 
readmission rates and overall costs[17]. Specifically 
for BJIs, during initial hospitalization, patients with 
osteomyelitis and septic arthritis had lower costs in 
the initial hospitalization if they had an early ID 
consult (versus no or late ID consult). 
Education of the next generation of 
Orthopaedic infectious diseases providers 
Most infectious diseases training programmes 
provide training in Orthopaedic infectious diseases as 
part of fellowship training. There are however few 
formal/dedicated training programmes. In the US, 
one such non-ACGME (Accreditation Council for 
Graduate Medical Education) programme is available 
at the Mayo Clinic in Rochester, MN, USA (1-year 
subspecialty orthopaedic infectious diseases 
fellowship). Emphases of the fellowship include 
participation in multidisciplinary team management 
of patients with both musculoskeletal infections from 
the common to complex and research opportunities in 
BJIs. Other high-volume BJI units regularly receive 
physician-trainees or fellows for further clinical 
training and research, and these are important in the 
building up of expertise and future generations of 
orthopaedic infectious diseases providers. The EBJIS 
has recognized this opportunity and organizes 
travelling fellowships since 2014[18]. Each year, three 
fellows among all applicants will be awarded and 
offered the chance to visit three or four distinguished 
European Centers specializing in BJIs.  
Societies that focus on BJIs 
At the societal level, professional bodies 
dedicated bodies to advancing knowledge and best 
practices in the management of musculoskeletal 
infections besides the EBJIS (founded 1993) include 
the Musculoskeletal Infection Society (MSIS, founded 
1989) and International Working Group on the 
Diabetic Foot (IWGDF, founded 1996). These, 
alongside other speciality professional societies (for 
e.g. the Infectious Diseases Society of America (IDSA), 
the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID), the European Society 
of Paediatric Infectious Diseases (ESPID), European 
Association of Nuclear Medicine (EASN), the 
American Academy of Orthopaedic Surgeons (AAOS) 
and consensus groups (e.g. the International 
Consensus Meeting (ICM) on surgical‐site infection 
and periprosthetic joint infection) have promoted 
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dialogue, research, consensus and promotion of 
evidenced-based practise through various guidelines 
and meetings, covering important areas such as 
diagnostic tools and criteria for PJIs and its 
management, and other BJIs [19–23]. Several 
BJI-specific scientific meetings are also held regularly 
– these include the Oxford Bone Infection Conference 
(OBIC), MSIS and EBJIS meetings. 
Definition and Classifications – the basis 
for translational and clinical studies 
For many decades, providers classified and 
categorized BJIs. The heterogeneity of cases and 
definitions in clinical practice and attendant clinical 
data caused a burden for useful conclusions. The 
collaborations of orthopaedic and trauma surgeons 
and ID physicians have led to a continuously evolving 
and improved structure in defining and 
understanding osteomyelitis of long bones [24,25], 
fracture related infections [26] and prosthetic joint 
infections[22] .  
Gaps and future directions 
The recent decades have seen strides in the 
management of BJIs. From a scientific and clinical 
perspective, these fall into distinct areas as nicely 
outlined by the ICM: microbiology/antimicrobials, 
biomaterials/implants, surgery/clinical care, and 
immunology/host immunity (such as vaccines to 
prevent BJIs), although the last has been the most 
nascent in terms of scientific discovery/ 
breakthroughs, and should receive more attention 
and funding [19]. From a clinical front, recent trials 
such as OVIVA which have questioned traditional 
paradigms such as the length of intravenous 
antimicrobial therapy for osteomyelitis are potential 
game-changers and a reminder that specialists in BJI 
are best-placed, as a community, to conduct these 
pivotal trials and gather evidence which will inform 
practice [27]. With evolving technology, the field 
would need to also address the place of newer 
techniques such as metagenomics and proteomics, 
and novel biomarkers for the diagnosis of BJIs. 
Antimicrobial resistance and a lack of suitable 
antimicrobial therapy, particularly in chronic and 
biofilm-associated infections, is also an area which the 
orthopaedic infectious diseases specialists need to 
confront. Most importantly, greater efforts need to be 
put into preventive strategies, which are always 
‘better than cure’. Some of these would entail new 
scientific discoveries; however a lot of these may be 
done with what we already know – such as waging 
the war on diabetes (and its attendant global burden 
of foot infections).  
Orthopaedic ID has matured into a subspecialty 
in its own right. National and international societies 
should continue to develop formal training programs, 
certification, and recognise centers with excellence in 
this field. The management of BJIs is often nuanced 
and complex and the Orthopaedic ID subspecialists 
bring much to the table in the prevention and 
management of BJIs. 
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